Seeing Is Believing
Currently out of the existing stock ratings of Matthew Luchini, 45 are a HOLD (35.71%), 81 are a BUY (64.29%).
Analyst Matthew Luchini works at BMO with a stock forecast success ratio of 41.84% fulfilled within 117.67 days on average.
Matthew Luchini’s has documented 265 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on REPL, Replimune Group at 18-Mar-2022.
Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 6/6/2017. The price target of $69.95 was fulfilled within 1 day with a profit of $6.38 (10.04%) receiving and performance score of 100.36.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
0.4
$0.01 (2.56%)
1 years 5 months 30 days ago
1/1 (100%)
$0.01 (2.56%)
2
Buy
1 years 6 months ago
1/10 (10%)
$13.99 (348.88%)
848
Hold
12
1 years 6 months ago
0/2 (0%)
$2.73 (29.45%)
Hold
1 years 6 months 1 days ago
0/1 (0%)
$7.55 (308.16%)
Hold
11
1 years 6 months 26 days ago
0/2 (0%)
$6.72 (157.01%)
What Year was the first public recommendation made by Matthew Luchini?